Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01220232 · ClinicalTrials.gov registry record · Phase 1
Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01220232 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 14 participants.
The verdict
NCT01220232, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This will be an open-label, fixed-sequence, multiple dose crossover study in 14 healthy male and/or female subjects, to estimate the effect of steady state lersivirine on the steady state pharmacokinetics of abacavir/lamivudine.
Interventions
- DRUG Abacavir/Lamivudine
- DRUG Lersivirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01220232
The ClinicalTrials.gov registry entry for NCT01220232 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Abacavir/Lamivudine is the first listed.
NCT01220232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01220232 about?
NCT01220232 is a clinical study titled "Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects". This will be an open-label, fixed-sequence, multiple dose crossover study in 14 healthy male and/or female subjects, to estimate the effect of steady state lersivirine on the steady state pharmacokinetics of abacavir/lamivudine.
What is the current status of trial NCT01220232?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2010-11. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01220232?
The interventions under investigation include: Abacavir/Lamivudine (DRUG), Lersivirine (DRUG).
Who is sponsoring clinical trial NCT01220232?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.